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Abstract
Introduction: For many rare diseases, strong analytic study designs for evaluating the efficacy and effectiveness of
interventions are challenging to implement because of small, geographically dispersed patient populations and
underlying clinical heterogeneity. The objective of this study was to integrate perspectives from published literature
and key rare disease stakeholders to better understand the perceived challenges and proposed methodological
approaches to research on clinical interventions for rare diseases.
Methods: We used a meta-narrative literature review and focus group interviews with key rare disease stakeholders
to better understand the perceived challenges in generating and synthesizing treatment effectiveness evidence,
and to describe various research methods for mitigating these identified challenges. Data from both components
of this study were synthesized narratively according to research paradigms that emerged from our data.
Results: Results from our meta-narrative literature review and focus group interviews revealed three fundamental
challenges in generating robust treatment effectiveness evidence for rare diseases: i) limitations in recruiting a sufficient
sample size to achieve planned statistical power; ii) inability to account for clinical heterogeneity and assess treatment
effects across a clinical spectrum; and iii) reliance on short-term, surrogate outcomes whose clinical relevance is often
unclear. We mapped these challenges and associated solutions to three interrelated research paradigms: i) explanatory
evidence generation; ii) comparative effectiveness/pragmatic evidence generation; and iii) patient-oriented evidence
generation. Within each research paradigm, numerous criticisms and potential solutions have been described with
respect to overcoming these challenges from a research study design perspective.
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Conclusions: Over time, discussions about clinical research for interventions for rare diseases have moved beyond
methodological approaches to overcome challenges related to explanatory evidence generation, with increased
recognition of the importance of pragmatic and patient-oriented evidence. Future directions for our work include
developing a framework to expand current evidence synthesis practices to take into consideration many of the
concepts discussed in this paper.
Keywords: Rare diseases, Evidence generation, Comparative effectiveness, Patient-oriented outcomes, Evidence
synthesis, Research methods,
Background
For many rare diseases, strong analytic study designs for
evaluating the efficacy (does intervention X work under
ideal conditions?) and effectiveness (does intervention X
work in real-world practice?) [1] of interventions are
challenging to implement because of small, geographic-
ally dispersed patient populations and characteristically
high clinical heterogeneity [2]. A poor understanding of
natural history for many rare diseases, scarcity of vali-
dated measures of disease progression, and various
financial constraints (e.g., limited availability of research
funding, high costs of trials for rare diseases) also add to
the complexity of evaluating treatments for rare diseases
[2–4]. As a result of these limitations, it is often not
feasible to conduct conventional randomized controlled
trials (RCTs), the gold standard for determining treat-
ment efficacy [5]. Thus, rare disease researchers must
often rely on other study designs that are more prone to
bias when evaluating interventions, such as open label
or uncontrolled trials, observational studies, and case
reports. [6, 7]
The evidence that exists for clinical interventions for rare
diseases therefore typically falls in the bottom half of the
traditional evidence hierarchy [7, 8] and is methodologic-
ally flawed [6, 9]. For example, a recent systematic review
of available evidence for 11 orphan medicines found that
case studies represented the largest proportion (140/338;
41%) of study designs used to determine clinical effective-
ness, while only 7% (14/338) of studies were double-blind,
placebo-controlled RCTs [6]. Studies that have reviewed
the evidence for clinical interventions for rare diseases that
is submitted to regulatory and health technology assess-
ment agencies in support of marketing authorization and
reimbursement approval have also found limited RCT evi-
dence for some rare diseases, particularly those considered
‘ultra-rare’ [10–13]. Newer processes for both regulatory
approval and reimbursement approval may be shifting the
standards in terms of evidence requirements in this rapidly
evolving area [14–16]. A recent analysis of ClinicalTrials.gov
comparing characteristics of completed or on-going trials
for rare and non-rare disease treatments demonstrated that
trials for rare disease therapies are likely to enroll fewer par-
ticipants, be single arm, non-randomized, and open label
[17], all of which can compromise the internal validity of a
study.
The lack of high quality evidence and the typically
high cost of clinical interventions for rare diseases com-
monly result in debates about the efficacy and effective-
ness of these interventions among stakeholders [18, 19].
Disagreements about the evidence arise from differing
views about the methodological rigour of the study de-
sign; what constitutes a meaningful outcome; and the
minimal clinically important difference for a relevant
outcome [20]. Disputes among stakeholders are further
fueled by differing values and the institutional/political
landscape surrounding decision-making processes about
interventions for rare diseases [20, 21]. As a result,
health policy recommendations, such as those concern-
ing reimbursement for some clinical interventions for
rare diseases, are variable across jurisdictions [22, 23].
The objective of this study was to integrate perspec-
tives from published literature and key rare disease
stakeholders to better understand the challenges and
approaches to research for clinical interventions for rare
diseases. More specifically, we sought to:
(1) identify perceived challenges in generating robust
evidence for establishing treatment efficacy and
effectiveness in the context of rare diseases; and
(2) describe various clinical evaluative research methods
that have been suggested for mitigating the identified
challenges in generating robust evidence, focusing on





An initial scoping of the literature regarding our re-
search topic revealed diverse perspectives on generating
evidence for efficacy and effectiveness of treatments for
rare diseases. We therefore chose to use an adaptation
of the meta-narrative approach developed by Greenhalgh
and colleagues specifically for systematically reviewing
the literature on complex topics that have been concep-
tualized and studied differently among researchers [24].
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Meta-narrative reviews encompass six main principles:
(1) pragmatism, the included information should be
driven by usefulness to the intended audience; (2) plur-
alism, the topic should be considered from multiple per-
spectives; (3) historicity, the included information should
be presented according to its development over time; (4)
contestation, any conflicting information should be used
to generate higher-order insights; (5) reflexivity, there
should be continual reflection on the review findings;
and (6) peer review, the review findings should be pre-
sented to an external audience for feedback [24, 25].
Below we describe the methods for each phase of our re-
view separately and sequentially, while recognizing that
the phases overlap with each other [24].
Planning and search phases
Our interdisciplinary study team has expertise in epi-
demiology, health services research, health economics,
and information science. We held a series of meetings to
discuss the emerging findings from the literature and
provide direction as the project progressed. We also
agreed that the outputs from this review would include a
summary of current knowledge across research para-
digms on the topic of establishing efficacy or effective-
ness for clinical interventions for rare diseases, and a
framework to guide future evidence syntheses in this
field (currently under development).
We used an initial exploratory search (snowball sam-
pling and citation-searching) to identify important
sources of information relevant to our study objectives,
and in turn, developed a formal search strategy com-
prised of Medical Subject Heading (MeSH) terms and
keywords. Our search strategy was developed iteratively
(by LS and KT) and was not meant to be exhaustive, but
was designed to identify key sources of scholarly infor-
mation. Three electronic databases were searched: MED-
LINE (Ovid MEDLINE (R) In-Process & Other
Non-Indexed Citations and Ovid MEDLINE (R) 1946 to
June 21, 2017), EMBASE (Embase Classic + Embase
1947 to June 21, 2017), and PubMed. Search strategies
for each database can be found in Additional file 1. We
also scanned reference lists from included studies for
any additional citations.
All citations returned from the searches were reviewed
using a two-stage approach. During the first stage, one
member of the study team (KT) scanned titles and ab-
stracts of all citations to identify potentially relevant re-
cords. For the second stage, full-text articles were
retrieved for all citations identified during stage one, and
one member of the study team (KT) reviewed the arti-
cles to determine final inclusion/exclusion. Given that
the purpose of the search and screening phases was to
identify key sources of information rather than to be
exhaustive, and that the meta-narrative approach is
reflexive by design, having only one member of the team
screen citations and papers for eligibility was deemed
appropriate. To help mitigate bias, we established the
following inclusion criteria: (i) relevant to rare diseases
or orphan medicines; and (ii) describes methods used to
overcome challenges for establishing efficacy or effect-
iveness of clinical interventions for rare diseases. We did
not limit inclusion to primary studies (i.e., review articles
were included), but did exclude letters to the editor, con-
ference abstracts, and commentaries. We also did not
limit according to specific diseases or disease groups.
Finally, given language constraints within the team, we
excluded all articles not written in English.
Mapping, appraisal and synthesis phases
A fundamental aspect of the meta-narrative approach is
constructing a story about how research on a given topic
has unfolded over time [24, 25]. To this end, we
extracted information from each report to identify key
people, events, research questions, conceptual and the-
oretical issues, research findings, and areas of debate or
disagreement. Data extracted from each study included
(if applicable): bibliographic characteristics (publication
date, author(s), geographical location), sponsorship/de-
clared conflicts of interest, and report characteristics
(type of study, disease(s) of interest, study objectives,
main findings/conclusions, etc.). Additionally, we used
the following guiding questions to extract further infor-
mation to describe the different perspectives:
1. What study designs have been described for studying
the efficacy or effectiveness of treatments for rare
diseases?
2. What strengths, weaknesses, and risks of bias are
reported as important for each study design?
3. What are the described tradeoffs in risk of bias
among the study designs?
4. Is the choice of outcome(s) reported as an influence
on the quality of evidence?
Data were extracted from each report by a single re-
viewer (KT) and findings were reviewed and discussed at
team meetings. Bibliographic and report characteristics
were synthesized descriptively, and all other study find-
ings were synthesized narratively.
Focus group interviews with stakeholders
Design, sampling, recruitment, and participants
In parallel with the meta-narrative review, we conducted
focus group interviews with three stakeholder groups to
better understand their perspectives on generating evi-
dence for clinical interventions for rare diseases. We
recruited a convenience sample from three groups who
could speak knowledgeably (based on formal knowledge
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or experience) about evidence for interventions for rare
diseases, including: physicians, policy advisors, and rare
disease patients or caregivers. More specifically, we
chose to include rare disease patients and caregivers as
stakeholders because they are directly impacted by clin-
ical research and could provide unique perspectives
based on their lived experiences, especially in regards to
outcomes that reflect quality of life and in considering
how the selection of outcomes affects the relevance of
the evidence produced. To facilitate the focus group dis-
cussions with physicians and patients/caregivers, we
chose rare inherited metabolic diseases as a case study.
For the patients/caregivers, we further narrowed the se-
lection to mucopolysaccharidoses (MPS), a group of rare
metabolic conditions, because this group of diseases
typifies the characteristics of many rare diseases that
present challenges for conducting strong analytic stud-
ies, including low prevalence (i.e., very small population),
significant clinical heterogeneity, and, for some MPS
types, the existence of expensive orphan drug treatments
that require evaluation. In addition, this restriction sup-
ported an in-person discussion with patients/caregivers
as we could meet with that group as part of an annual
event (described below). We sought between five and
eight participants per focus group, based on standard
focus group interview methodology [26]. Individuals
were eligible to participate if they had experience with
the care of those diagnosed with a rare inherited meta-
bolic disease (metabolic physicians), if they had experi-
ence in evidence review activities that result in
recommendations being made about the development,
use, and/or reimbursement of interventions for rare
diseases (policy advisors) or if they were adults diag-
nosed with MPS or a related disease, or were the care-
giver (i.e., parent/guardian) of someone diagnosed with
MPS or a related disease.
Recruitment invitations were distributed by email to
physician members of the Garrod Association (a profes-
sional association whose members are involved in caring
for patients with inherited metabolic diseases), to policy
advisors by a member of their professional network
(using publicly available contact information), and to pa-
tients/caregivers attending the Canadian MPS Society’s
2017 Annual Family Meeting. Individuals interested in
participating were instructed to contact a member of the
research team (KT), and eligible respondents were asked
to provide signed, informed consent to participate in the
study. Focus group interviews were conducted by tele-
phone with the physicians and policy advisors, and
in-person with the patients/caregivers in conjunction
with the Canadian MPS Society’s 2017 Annual Family
Meeting held in Montreal, QC, Canada. The study proto-
col was approved by the Ottawa Health Science Network
Research Ethics Board and the Children’s Hospital of
Eastern Ontario Research Ethics Board (physicians and
policy advisors), and the University of Ottawa Health Sci-
ences and Sciences Research Ethics Board (patients/
caregivers).
Data collection
Focus group interviews were conducted by a single
member of the study team (KT) using a semi-structured
interview guide and were attended by a second member
of the team as an observer (BKP or JJM). The interview
guide was tailored to the specific stakeholder group. The
interview guide addressed general perspectives on the
challenges of rare disease research, and more specific
topics including generation and synthesis of evidence to
establish treatment efficacy or effectiveness, and out-
comes used in clinical evaluative studies. All interviews
were audio-recorded with participants’ consent and sub-
sequently transcribed.
Data analysis
Each focus group transcript was analyzed using a quali-
tative descriptive approach that is aimed at “obtaining
straight and largely unadorned (i.e., minimally theorized
or otherwise transformed or spun) answers to questions of
special relevance to practitioners and policy makers”
[27]. Four members of the study team (KT, BP, DC, IG)
met to identify the key concepts and themes that were
present in the focus group data. These concepts/themes
were organized into a coding system that was applied by
one study team member (KT) using NVivo 10 Software
(QSR International Pty Ltd.) and reviewed by a second
member (BP) for credibility and trustworthiness [28].
Results
Search & screening results
Electronic database searches returned 2871 records after
removal of duplicates, of which 161 records were identi-
fied as potentially relevant based on the title and abstract
scan. An additional 14 titles were identified as poten-
tially relevant from scanning reference lists of included
studies. Full text articles were successfully obtained for
172/175 records. Of the 172 full-text articles reviewed,
60 articles were included in this review (Fig. 1 [29]).
Descriptive study characteristics
Of the 60 articles we reviewed, 57 (95%) were published
after 2000 (Table 1; Fig. 2). Based on the location of the
corresponding author address, 27/60 articles (45%) were
written by authors from the United States, 8 (13%) from
authors in Canada, 5 (8%) from authors in the United
Kingdom, and the remaining articles were written by
authors across Europe and Australia (Table 1). Sixteen
(27%) articles explicitly reported that their study was
sponsored by industry or had some affiliation with
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industry, while conflicts of interest/study sponsorship
were not explicitly reported for a further 14 (23%). Over
half of the included studies (33/60; 55%) reported on
rare diseases in general, while the remaining articles
focused on a specific disease or group of diseases. A ma-
jority of the articles included were review articles of
research methods used to evaluate efficacy or effective-
ness of interventions for rare diseases (39/60; 65%); how-
ever, 28% (17/60) described the application of a specific
research method in the rare disease context (Table 1).
While most of the articles reviewing methods were fo-
cused on rare diseases generally (26/39, 67%), many of the
applied studies were specific to single diseases (13/17,
76%). A list of the included articles can be found in
Additional file 2.
Description of focus group participants
We held three focus group interviews with 13 partici-
pants in total (physicians n = 6; policy advisors n = 3;
patients/caregivers n = 4). Across the three groups
there were 9 women and 4 men. Participants were
from 5 provinces in Canada: British Columbia,
Alberta, Ontario, Quebec, and Newfoundland and
Labrador.
Research paradigms in establishing efficacy or
effectiveness of clinical interventions for rare diseases
Three overlapping research paradigms through which stake-
holders view the challenges and prioritize potential solutions
for establishing efficacy or effectiveness of clinical interven-
tions for rare diseases emerged from our data: (1) explana-
tory evidence generation, (2) comparative effectiveness/
pragmatic evidence generation, and (3) patient-oriented evi-
dence generation. The findings from our literature review
and focus group interviews are discussed according to each
of these paradigms. While each research paradigm is
discussed separately, they are not mutually exclusive. A
summary of perspectives across the three research para-
digms is provided in Table 2.
Explanatory evidence generation
Much of the discussion in the literature and amongst
focus group participants concerning evaluative clinical
research in rare diseases centered on problems
Records identified through 
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Fig. 1 PRISMA flow diagram outlining results from search and screening process. (Adapted from: Liberati et al. 2009) [29]
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associated with the inherent small numbers of patients
available for study and adequate recruitment for conven-
tional RCTs, long considered the gold standard explana-
tory design with a low risk of bias [5].
“I do find it quite difficult when the clinical trials are
very short, very small numbers, and the endpoints are
something like the six minute walk test in regards to
really being confident that that is going to be an
effective treatment for the patients that I’m seeing.”
– Physician 4
“For common diseases, there’s no reason for not
doing a randomized controlled trial. I mean, that’s
one of the big points in the paper that we published
a few years ago was that in order to be called rare,
you should not have enough patients to confidently
determine whether a treatment is efficacious or
not.” – Policy Advisor 1
“Well the ex-[profession] in me looks at things like,
you know, the size of the study, well MPS is [laughter
around the table], okay that’s not going to happen.
You know, so you have to, it’s hard when you’re
looking at MPS because the things that you would
normally look for in a good study aren’t going to be
there because of the size of the sample…” – Patient/
caregiver 3
Table 1 Descriptive characteristics of included studies (n = 60)








2015-present (June 21, 2017) 8 (13)
Country (corresponding author address)
United States 27 (45)
United Kingdom 5 (8)
Canada 8 (13)
France 4 (7)







Industry affiliations 16 (27)
None (no conflicts of interest declared) 24 (40)
Other (e.g., government funding) 6 (10)
Not explicitly reported 14 (23)
Disease/disease group of focus
Rare diseases in general 33 (55)
Disease groups:
Inherited metabolic diseasesa 2 (3)
Lysosomal storage disorders 3 (5)
Pediatric rheumatic diseases 1 (2)
Rare lung diseases 2 (3)
Rare neonatal diseases 1 (2)
Rare neurodegenerative diseases 1 (2)
Rare renal diseases 1 (2)
Individual disease(s):
Alpha1-antitrypsin deficiency & pulmonary alveolar
proteinosis
1 (2)
Batten Disease 1 (2)
Childhood polyarteritis nodosa 2 (3)
Duchenne muscular dystrophy 1 (2)
Familial hypercholesterolemia 1 (2)
Familial Mediterranean fever 1 (2)
Gaucher disease 1 (2)
Hemophilia A 1 (2)
Late-onset Pompe disease 1 (2)
Table 1 Descriptive characteristics of included studies (n = 60)
(Continued)
Study characteristic Number of
studies (%)




Primary sclerosing cholangitis 1 (2)
Scleroderma 2 (3)
Vasculitis (rare form) 1 (2)
Types of studies
Review article of multiple research methods 28 (47)
Review article of a single research method 11 (18)
Application/case example of research method 17 (28)









Patient-oriented evidence generation 15 (25)
anot mutually exclusive as some studies discussed more than one
research paradigm
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This paradigm was discussed by more than half (35/
60, 58%) of the studies we reviewed, and was also the
first that emerged in the literature in 1992 (Fig. 2). Most
of the reports that discussed this paradigm were meth-
odological review articles that focused on rare diseases
in general or a group of rare diseases (24/35, 68%),
rather than a single specific rare disease. The first author
to highlight the challenges associated with fewer partici-
pants for clinical studies was Haffner, who took the per-
spective of a regulatory agency responsible for reviewing
the safety and efficacy of orphan medicines [30, 31].
Haffner argued that orphan medicines should be as
well-scrutinized as medicines for more common diseases
but recognized that conventional RCTs are not always
feasible due to small numbers [30, 31]. Some alternative
research methods or design features for demonstrating
safety and efficacy that may be acceptable to a regulatory
agency were suggested, including the use of multicenter
studies, crossover trials, randomized withdrawal trials,
open label studies, open protocol studies, and incorpor-
ating historical controls or composite or surrogate end-
points [30, 31]. The discussion concerning explanatory
evidence generation for clinical interventions for rare
diseases continued from these early publications to the
present day (Fig. 2). Others elaborated on the issues
brought forth by Haffner and offered more suggestions
to overcome the challenges related to small numbers
and limited feasibility of conventional RCTs, while pre-
serving internal validity and protecting against bias and
confounding [2, 4, 18, 32–61].
While participants in our focus groups highlighted the
limited feasibility of conventional RCTs because of small
sample sizes, there was little emphasis in the focus
group discussions on specific strategies that might be
used to overcome this challenge. Thus, most of the
results presented under the paradigm of explanatory evi-
dence generation are derived from our meta-narrative
literature review.
In general, the research methods or study design fea-
tures that have been proposed in the literature to ad-
dress small numbers while retaining internal validity and
thus an explanatory focus have concentrated on three
overarching strategies: (i) enhancing statistical efficiency
at the design phase, so that fewer participants are re-
quired to conduct a robust evaluation; (ii) using Bayesian
rather than frequentist analysis methods, also to reduce
the number of participants required; and (iii) making
participation more appealing to patients and families by
maximizing time spent on the active treatment. Several
methodological reviews were published on this topic in
the last decade [36, 39, 40, 42, 45, 46, 61], some of which
provided more detail about the methods described below;
here we focus on the most commonly suggested research
designs that focus on minimizing bias to maximize
internal validity and explanatory power.
Strategies that have been proposed for enhancing stat-
istical efficiency at the design phase for clinical evalu-
ative studies of rare disease treatments include factorial
trials and adaptive designs. Factorial trials are designed
to test multiple treatments simultaneously using the
same study population, thus reducing the overall num-
ber of participants needed [2, 33, 39, 40, 46, 49, 53, 57].
For example, in a 2 × 2 factorial design participants are
randomized to either treatment A or control group A,
and then randomized again to treatment B or control
group B, which effectively reduces the sample size
needed to test these two treatments by 50% because the
same participants are being randomized [40]. However,
authors have pointed out that this reduction in sample
size only holds assuming there is no interaction between
Fig. 2 Research paradigms discussed by year of publication (note: research paradigms are not mutually exclusive)
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the treatments being administered concurrently; other-
wise, statistical efficiency is lost [40]. Adaptive designs
allow flexibility in trial procedures such that changes
(“adaptations”) based on interim analyses can be made
after trial initiation without undermining the validity of
the trial [59]. Two commonly discussed adaptive trial
strategies are response-adaptive randomization and
group sequential design [36, 40, 46, 53, 59, 61].
Response-adaptive randomization involves modifying
treatment assignment probabilities with the accrual of
data so that the number of participants randomized to
the best-performing treatment arm (“play-the-winner”)
is increased and overall sample size is decreased [59].
Group sequential designs do not have a predetermined
sample size, rather, small groups of participants are re-
cruited over several phases and data are analyzed at the
end of each phase to assess safety, futility, efficacy, or a
combination of these until enough data have been ac-
crued to justify study termination [59, 61]. Simulation
studies have shown that sequential design approaches
may, but do not always, reduce the eventual sample size
compared to fixed sample size designs [35, 53, 62].
While adaptive trial strategies are often reported as a
means to enhance statistical efficiency, some authors
have questioned their usefulness based on the paucity of
published practical application in the context of rare dis-
eases [40, 59].
For conventional RCTs with small sample sizes, achiev-
ing sufficient statistical power to detect differences in
treatment effects, especially when the treatment effect is
expected to be modest, is challenging [52]. Several authors
have argued (as early as 1995) that Bayesian techniques
would be better suited in this context relative to standard
frequentist approaches to analysis, because a Bayesian
analysis is not as compromised by small numbers and of-
fers more direct conclusions [32, 34, 41, 44, 45, 48, 50–
52]. In such approaches, previously collected data or ex-
pert opinion is used to generate a prior probability (pos-
terior) distribution for the unknown treatment effect, and
Bayes theorem is applied as new data are accumulated to
update the posterior distribution for the new treatment
and inform clinical practice [48, 52]. As an example,
Johnson and colleagues reanalyzed data from an RCT of
methotrexate versus placebo in 73 patients with sclero-
derma, and demonstrated that methotrexate had more
favorable odds of being beneficial for patients when a
Bayesian approach was applied compared to the
non-statistically significant findings obtained through a
frequentist approach [32]. While several authors argued
that Bayesian statistics offer an alternative approach to the
analysis of small numbers of participants, some criticized
the subjectivity in establishing prior distributions and were
skeptical of the acceptance of results obtained using
Bayesian statistics at the regulatory level [34, 36, 45, 48].
It was reported in the literature and in our focus group
discussions that there can be a lack of patient/family/clin-
ician acceptance of the possibility of being randomized to
a control group, particularly for placebo-controlled studies
of treatments for rare diseases where few treatment alter-
natives exist. Therefore, study designs that make participa-
tion more appealing by maximizing time spent on- or
guaranteeing provision of- the active treatment have been
suggested [4, 33, 36, 38–42, 44–47, 49, 51, 56, 57, 60].
“I agree with [name]‘s comments that it’s hard to have
a placebo-controlled trial. I mean, certainly there has
been trials to try to do that. …however, they're very
short and really with these, like almost, like even to
encounter, to have families agreeable to participate
being a placebo for long-term, I think would be very
difficult. I think for the short-term, for a few months
or a year, families are agreeable, but after that I don’t
think they would be agreeable.” – Physician 2
The randomized placebo-phase design has the same
design features of a conventional RCT, except that the
time from enrollment in the study to the start of the
experimental treatment is randomized for all partici-
pants [56]. All participants eventually receive the experi-
mental treatment, and effectiveness is determined based
on whether a response is observed sooner among those
that received the treatment earlier [56]. Similarly, ran-
domized withdrawal, early escape, and stepped wedge
trials reduce time spent in a control arm or ensure that
all participants eventually receive the intervention being
studied, and have been proposed as alternative
approaches to evaluate clinical interventions for rare dis-
eases [40]. Crossover trials and n-of-1 trials also guaran-
tee that participants receive the active treatment, but are
different than conventional RCTs in that the treatment
sequence is randomized with a washout period in be-
tween treatment regimens, such that each participant
acts as his or her own control [2, 36, 41, 53, 57]. As
some authors reported, n-of-1 trials are often embedded
in clinical practice to help healthcare providers deter-
mine the best treatments for their patients [2, 36, 57].
While several authors have examined the advantages of
crossover and n-of-1 trials, others have discussed the
risk of carryover and period effects between phases, and
have argued that these designs are generally not suitable
for diseases that have an unstable disease course or for
interventions that are not fast-acting with reversible
effects [2, 18, 33, 36, 39, 44, 46, 53].
The three overarching strategies and associated
research methods discussed above are not mutually
exclusive, rather there is significant overlap among them
in the literature. For example, in addition to being an
attractive option for participants, crossover trials are also
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considered statistically efficient and reduce the number
of participants needed because each participant acts as
his or her own control [2, 18, 33, 36, 39, 40, 44, 46].
Huang and colleagues have suggested that statistical effi-
ciency could be further enhanced in crossover trials by
allowing participants to “escape early” [41]. Similarly, au-
thors have stated that trials using adaptive randomization
can be attractive to participants because the likelihood of
being randomized to the less effective treatment arm is
reduced over time [36, 40, 46, 53, 59, 61]. Bayesian
methods are also reported as a common design feature of
adaptive trials as a means of improving statistical effi-
ciency [34, 42, 59]. They have also been proposed as a
means to combine results from multiple n-of-1 trials and
enhance the usability of n-of-1 trial data in answering
population-level questions about treatment efficacy and
effectiveness [51].
A criticism of explanatory evidence generation re-
ported both in the literature and in focus group discus-
sions was that studies designed to evaluate the efficacy
of an intervention typically limit enrolment to a very
homogenous group of participants, which strengthens
the robustness of the causal interpretation of the find-
ings, but at the expense of a reduction in the external
validity or generalizability of study results [4, 18, 44, 60].
Because rare diseases typically exhibit substantial clinical
heterogeneity (discussed in the following section), some
authors have questioned the suitability of the
above-mentioned approaches for evaluating clinical in-
terventions for rare diseases [4, 18, 44, 60]. Additionally,
authors have argued that many conventional RCTs and
other explanatory studies are short in duration, often
due to resource constraints, and do not allow for ad-
equate assessment of long term treatment effects, fur-
ther compromising external validity [4, 18, 57]. Finally,
some authors were concerned that unfamiliar approaches
to research design, such as adaptive randomization or
n-of-1 trials would not be accepted by regulatory agencies
and other policy decision-making bodies [36]. Partly in
response to some of these concerns, other research para-
digms for evaluating clinical interventions for rare diseases
have evolved.
Comparative effectiveness/pragmatic evidence generation
It is well established that there is a high degree of clin-
ical heterogeneity among rare disease patients, such that
patients with the same specific disease might have dras-
tically different clinical manifestations based on patient
characteristics such as age, disease characteristics such
as residual enzyme activity levels, or for unknown rea-
sons, and may respond differently to a given interven-
tion [18, 42]. As several authors have discussed, this
clinical heterogeneity is often not accounted for in con-
ventional RCTs, and has raised concern among
stakeholders about the applicability of study results to
patients with clinical manifestations different from those
included in RCTs [4, 18, 44, 60].
“And I find it frustrating in terms of research what I’ve
found, and you guys know this, that each case is so
unique and different, and so when you read a study or
evidence-based research, I find that it, it’s not a guar-
antee that it’s going to directly correlate to your par-
ticular unique situation. So, you have to take that at
face value and not think that ‘oh because I read that
study and that it is evidence based that this is exactly
what’s going to pertain to my situation.” – Patient/
caregiver 4
“…there’s a huge heterogeneity of this population.
There’s people with very severe diseases, people with
very mild disease, and this is the nature of enzyme
deficiencies. There’s some people that have zero and
some people will have, a lot, near normal enzyme
activity, so we’re going to get this heterogeneity. And
this is one of the big problems, like [name] mentioned,
how do we apply this clinically to a larger population
of these patients? Are the results, for instance, with
infantile-Pompe, how do we relate that to an adult
Pompe patient?” – Physician 5
“…the way that the trials are designed, very sub, select
populations with the actual disease of concern, which
is already a narrow disease as it is. It makes it very
difficult for us to know where and when these
therapies are going to work. And so, when we’re talking
about rare diseases, it really has to be linked to not
just research, but effectiveness research about natural
history and epidemiology. And given the wide degree of
heterogeneity with the diseases that we’re dealing with,
we’re going into this with a huge degree of uncertainty
about whether or not there really is any evidence to
support that these therapies are going to work.” –
Policy advisor 2
In response to concerns about the external validity of
study results, several authors and focus group partici-
pants have advocated for study designs that may com-
promise internal validity to some extent, by shifting
away from the explanatory RCT, in order to address
real-world effectiveness [2, 4, 7, 18, 42, 44–47, 55, 57,
58, 63–80].
“…I think the effort like the Canadian group CIMDRN
to look at long-term outcomes, where there’s natural
selection of various treatment groups, I think will be
very helpful over the long term because of the chal-
lenges we have in doing strict study designs, and lack
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of financial supports for long-term studies. This effect
to observational studies and looking at outcome differ-
ences in naturally, sort of, selected difference maybe as
helpful in rare diseases I think as the designed stud-
ies.” – Physician 1
Almost 10 years after discussions about explanatory
evidence generation for clinical interventions for rare
diseases emerged in the literature, the research paradigm
of comparative effectiveness/pragmatic evidence gener-
ation started to develop (first discussion published in
2001). This paradigm was discussed by half (30/60, 50%)
of studies included in this review, and was first men-
tioned by Wilcken in 2001 [7]. Like the previous re-
search paradigm, most of the reports that discussed this
paradigm were methodological review articles that
focused on rare diseases in general or a group of rare
diseases (21/30, 70%), rather than a single rare disease.
Wilcken suggested that for some rare diseases, conven-
tional RCTs remained possible, but for others, observa-
tional studies with historical controls could be used to
evaluate treatment effectiveness [7]. Since that initial
publication, many authors have discussed research
designs that take a more pragmatic approach to evaluat-
ing treatment effectiveness in rare diseases, and often
explicitly attempt to include a broader patient popula-
tion and longer-term observation in natural settings.
These designs include: pragmatic clinical trials, observa-
tional studies (e.g., cohort studies and registries, case
series, case reports), and hybrid designs that incorporate
both randomization and systematic observation [2, 4, 18,
42, 44–47, 55, 57, 58, 63–80].
While participants in our focus groups questioned the
suitability of explanatory RCTs for establishing effective-
ness of clinical interventions for rare diseases, little of
the discussion focused on specific solutions to overcome
this challenge. Like the previous research paradigm,
most of the results presented under the paradigm of
comparative effectiveness/pragmatic evidence generation
are derived from our meta-narrative literature review.
Incorporating more pragmatic features into RCTs has
been suggested as a means to improve external validity
while maintaining the element of randomization to help
control for unmeasured confounding and maintaining
other standard methodological features of explanatory
RCTs, such as blinded outcome assessments [18, 45, 57].
These pragmatic RCTs feature design elements that bet-
ter reflect actual clinical practice, including: enrolling
participants with differing clinical presentations, taking
into consideration the system of care in which the new
treatment will be delivered (e.g., using standard-of-care
as a comparator instead of placebo), following partici-
pants for a longer period of time, and incorporating out-
comes that are meaningful from a patient/care provider
standpoint (patient-oriented research will be discussed
in the following section) [18, 45, 57]. Authors have criti-
cized pragmatic RCTs because they do still estimate
average treatment effects and thus are not necessarily
better suited to investigating potential heterogeneity of
treatment effects relative to explanatory RCTs [18].
Among the most common observational rare disease
research designs discussed in the studies we reviewed
are patient registries [4, 18, 42, 47, 58, 64, 65, 67, 72–74,
77, 80] and cohort studies [68, 78]. Because these obser-
vational studies do not typically have strict inclusion or
exclusion criteria for participants, nor do investigators
manipulate participants’ treatment(s), some authors have
argued these studies better reflect real-world clinical
practice and the clinical heterogeneity that typifies many
rare diseases [18, 42, 67, 72]. As reported in the litera-
ture, registries have multiple purposes including: evalu-
ating clinical- and/or cost-effectiveness of therapies;
monitoring safety of new or existing therapies; evaluat-
ing diagnostic tools; monitoring quality of care; and
assessing natural history over time [67]. We identified
several examples of registries being used to evaluate
treatment effectiveness of interventions for rare diseases,
for example, enzyme replacement therapy for lysosomal
storage disorders [72]. The International Collaborative
Gaucher Group Registry was established in 1991 and, at
the time of the publication of a paper by Jones and col-
leagues (2011), had collected longitudinal clinical data
for almost 6000 patients [72]. Several authors stated
that an additional advantage of registries is that they
can be used to identify potential participants for re-
cruitment into future research studies, including clin-
ical trials [18, 67, 73, 76, 77]. Some authors have also
suggested that observational patient registries may
play an important role in post-market evaluation of
interventions for rare diseases by serving as a plat-
form to collect longitudinal clinical and quality of life
data [47]. While observational patient registries are an
attractive method for the evaluation of longer term
outcomes in real-world settings, some authors re-
ported that results remain prone to residual con-
founding in the absence of randomization, especially
confounding by indication (when patient characteris-
tics influencing the choice of treatment also influence
the outcome) [18, 44]. A few authors discussed vari-
ability in the quality of registry data, as observational
patient registries tend to be heterogeneous in the
depth of data collection and the definitions applied to
included data elements, particularly in the context of
the multi-center and sometimes multi-national nature
of rare disease research [42, 65]. In addition, some
authors described the potentially important influence
of complete case ascertainment and data collection
on the accuracy of study results, particularly given
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that registry participation may be associated with re-
ceipt of particular treatments or lead to different in-
vestigations [67, 73, 81].
In recent years (since 2009), some authors have sug-
gested that elements of both explanatory and observa-
tional studies can be combined into “hybrid” study designs
that attempt to mitigate challenges faced by both ap-
proaches [18, 63, 75]. For example, Vickers and colleagues
suggested that the “clinically-integrated randomized trial,”
which seeks to integrate randomization into standard clin-
ical care, would be suitable for rare disease research,
addressing the threat of confounding while maintaining
an element of pragmatism and enhancing generalizability
[63]. The key feature of the clinically-integrated random-
ized trial is that there is no difference between the care a
patient routinely receives, follow-up, payment, or docu-
mentation (e.g., charting), other than the fact that treat-
ment was assigned randomly with informed consent from
participants [63]. In the context of rare diseases, the
authors argued that the clinically-integrated randomized
trial is attractive because there is often considerable uncer-
tainty about the most effective course of treatment for
patients and that trials could easily be conducted world-
wide to maximize the number of participants [63]. An-
other design that incorporates elements of both
explanatory and observational approaches and has been
suggested in the context of rare diseases is the “cohort
multiple randomized controlled trial (cmRCT)” [75]. The
cmRCT seeks to enroll an observational cohort of pa-
tients, with participants routinely reporting on a mini-
mum set of core outcomes [75, 82]. At the time of
enrollment in the cohort, participants give their consent
for 1) their longitudinal data to be used in aggregate; and
2) to be randomly selected to participate in potential RCTs
of new or existing interventions with the understanding
that only those who have been selected to be offered the
intervention under study will be contacted [75, 82]. Those
who are eligible for the RCT, but who were not randomly
selected to be offered the intervention serve as the control
group and are not contacted about the study [75, 82].
According to the literature, launching RCTs using this de-
sign increases the efficiency of research by accommodat-
ing multiple trials and comparison of multiple treatments,
allows for longer follow-up of participants, provides prag-
matic/real-world evidence, and accommodates clinical
heterogeneity by enrolling participants across the clinical
spectrum [18, 75, 82]. Concerns that have been raised with
these “hybrid” study designs include: potential for con-
founding and bias in the observational component of the
study, and the feasibility of implementing such a study
design [18, 75, 82].
Finally, there is discussion in this literature about
other observational designs such as case-control studies,
small case series and case reports; however, these
approaches are not commonly suggested as potential
solutions for improving pragmatic evidence generation
for establishing effectiveness of treatments for rare dis-
eases. Some authors have suggested that case-control de-
signs, where individuals who have experienced a certain
outcome (cases) are matched to and compared with in-
dividuals who have not experienced the outcome of
interest (controls), are well suited for studying rare dis-
eases, particularly in instances where there could be a
long lag time between the treatment and outcome of
interest [2, 80]. However, there are concerns about the
potential for introducing selection bias in choosing con-
trols [2]. Other authors have argued the importance of
case series and case reports in the context of establishing
treatment effectiveness for rare diseases [47, 66]. Case
series and case reports typically include in-depth infor-
mation related to clinical manifestations of disease, treat-
ment, and follow-up for a single patient or small group
of patients [47, 66]. While authors have acknowledged
there are clear limitations in terms of establishing treat-
ment effectiveness, they have argued that this evidence
can provide a better understanding of natural history for
many rare diseases, and can identify unexpected harms
or benefits of treatments, which could be of particular
importance for diseases considered “ultra-rare” [47, 66].
Similar to the concept of using case reports as pragmatic
evidence, several focus group participants reported rely-
ing on some anecdotal evidence to help inform
medical-decision making:
“I think all of the different information is important,
and including anecdotal, right? Because we deal with
very rare disorders sometimes, and you often go to
clinicians who have seen these conditions and have
treated them, and may take their point of view about
a certain treatment. So, you may say that’s anecdotal,
but it may be extremely valuable if there’s only a
handful of patients who have received that treatment.
So, I think all of the studies and designs, including
anecdotal evidence, I personally use that in
determining whether I think about a treatment for a
patient.” – Physician 1
“…sometimes it all depends on the experience of what
other people lived. Sometimes people tell you not to go
there because they’ve has a bad experience. So, I like to
have the bad and the good ones too, and then make
my mind and take better decisions.” – Patient 2
The main criticism in the literature for comparative
effectiveness/pragmatic evidence generation is the inher-
ent risk for bias and confounding because of the lack of
randomization; however, there have been efforts made to
mitigate this risk. As previously discussed, some authors
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have suggested incorporating pragmatic elements into
RCTs [18, 45, 57], while others have proposed methods
to overcome challenges in non-randomized studies. For
example, Cole and colleagues demonstrated the use of
case-control matching using the risk-set method for par-
ticipants enrolled in the International Collaborative
Gaucher Group Registry [69]. The authors applied this
method to balance “cases”, i.e., Gaucher patients with
skeletal avascular necrosis, and controls according to
demographic and clinical factors [69]. Use of propensity
scores to match participants has also been suggested as
a means of reducing the risk of bias in observational
studies of rare diseases [44].
Patient-oriented evidence generation
One of the main criticisms, both in the literature and by
focus group participants, of highly internally valid, ex-
planatory study designs is their tendency to rely on
short-term, and often surrogate, outcomes that are not
necessarily clinically meaningful [9].
“Most of the time study with rare diseases rely on
surrogates and the surrogates are selected usually on
the basis of biochemical indicators of some biological
activity of the treatment. And so, for enzyme
replacement therapy, the reduction in the concentration
of a substrate in urine or blood is regarded as evidence
of a biological pivot, a biological activity, but there’s far
too many examples where a surrogate, such as the one
I’ve just described, are really, there’s no relationship to
what the clinical outcomes are.” – Policy Advisor 1
“…I have a concern that sometimes outcome measures
are defined by what funding and drug approval
[agencies] like FDA want to see, right? [chuckles].
Rather than what the clinician may feel for a
particular rare disease is far more important. …it
becomes challenging to design appropriate studies and
pharma is at the end of the day interested in getting
approval and funding approval, and may target
outcome measures that are demanded by various
bodies rather than perhaps going for the most
clinically appropriate outcome measures.”
– Physician 1
Only in the last decade (Fig. 2) has a discussion in the
literature emerged regarding the importance of
patient-oriented evidence generation in rare diseases
(the first appearing in 2010). This discussion emphasizes
the need for outcomes that are of direct importance to
patients and caregivers. Fifteen of 60 reports (15/60,
25%) discussed issues related to the paradigm of
patient-oriented evidence generation, making it the re-
search paradigm with the smallest proportion of
literature. The majority of reports that discussed this
paradigm were again methodological review articles (13/
15, 87%), and the remaining two articles described case
examples specific to one rare disease.
Connected to the paradigm of explanatory evidence
generation, some authors have suggested the use of surro-
gate outcomes as proxies for patient-oriented outcomes
such as survival or quality of life because they can be mea-
sured relatively quickly and require fewer participants to
reach statistical efficiency [33, 83–85]. For example, in
2010, Kinder and colleagues reported that functional out-
comes such as exercise tolerance, survival, and quality of
life were the most salient outcomes to consider for rare
lung disease studies because they have undeniable mean-
ing for patients; however, the authors also described the
limited feasibility of conducting explanatory RCTs that in-
clude these outcomes and argued that surrogate outcomes
could therefore be developed and used as proxies for
patient-oriented outcomes [33]. Several authors and focus
group participants expressed concern about the lack of
validation of surrogate outcomes; a clear understanding of
the natural history of disease and proposed causal mech-
anism of a treatment in relation to the disease is needed
in order to establish, with reasonable certainty, the rela-
tionship between surrogate and patient-oriented outcomes
[33, 70, 73, 85, 86].
“…in order to identify reasonable outcomes measures
for any clinical trial, one has to know the what the
natural history of the disease is. So, those are major
challenges, and what we’re faced with in the
pharmaceutical industry, who are anxious to do as
short a study as possible, for rare disease almost
always use surrogate markers as evidence of
effectiveness and the relationship between the
surrogate marker and clinical outcome is often
completely unknown.” – Policy Advisor 1
For example, the six-minute walk test (6MWT) is a
common surrogate outcome measure used in clinical
evaluative studies for many rare diseases [83, 84, 87].
The 6MWT was originally developed for patients with
moderate to severe lung disease as a means of assessing
overall functional status and as a predictor of morbidity
and mortality [88] but has since been used in studies of
many rare diseases, including late-onset Pompe disease
and Duchenne muscular dystrophy, among others [84,
87]. An important criticism of this extension of its use is
the lack of adequate validation to determine if observed
changes in the 6MWT reflect meaningful changes for
patients [83, 84, 87].
“For me I think one of the big issues is the outcome
measures that we’re trying to document. For instance,
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with the lysosomal storage diseases, what is the
relevance of a 6 minute walk test? What is the clinical
relevance of this type of test?” – Physician 5
Partly in response to concerns about the relevance and
validity of surrogate outcomes being used in clinical re-
search for interventions for rare diseases, there has been
a shift towards incorporating patient-oriented outcomes
in clinical research [4, 42, 45, 74, 89].
“…because yes, scientific research is important too, but
it’s this push-pull dichotomy between the happiness,
the living life, just the simple moments, you know, go-
ing outside, sitting in the sun, that type of, going down
to the beach, those things need to be equally mea-
sured…” – Patient/caregiver 4
“We need to know more what’s going to happen in
terms of lifespan, in terms of morbidity, in terms of the
operations these patients are getting, in terms of
growth as well. Is this something that we’re seeing
improvement?” – Physician 5
“I think that [name] made reference to this earlier
about the importance of evaluating quality of life. And
unfortunately, this is not really done. I don’t know of a
single study that has done this rigorously for the
diseases that I happen to be involved with or have
been. And so, for example, the fact that a child may
require an intravenous infusion of some medication
that takes six hours of infusion and needs it every
week. They’re missing a day of school every week.
That’s twenty percent of their schooling! This is never,
in my experience, never evaluated. Now that’s not a
direct measure of quality of life, but you could easily
imagine that it would have a significant indirect
impact on quality of life.” – Policy Advisor 1
In the literature and among our focus group partici-
pants, much of the discussion regarding patient-oriented
outcomes has focused on developing outcomes that are
meaningful based on the lived experiences of patients
and their caregivers [18, 42, 74, 89]. Tudur Smith and
colleagues used the example of juvenile idiopathic arth-
ritis to demonstrate that clinical research initially fo-
cused on outcomes related to clinical disease activity
and disease damage, but more recently has shifted to
identifying and validating outcomes that are most im-
portant to patients and parents, such as health related
quality of life, functional assessments, and pain assess-
ments [45]. Basch and Bennett advocated for the use of
patient-reported outcomes in clinical studies for inter-
ventions for rare disease as the best measurement tools
for how a patient feels and functions [89]. Participants in
our focus groups also expressed a desire for researchers
to incorporate outcomes beyond those directly related to
the patient, including parent- and family-related
outcomes.
“One quick comment about the whole family because
I know, obviously, a lot of this is directed towards the
patient, the person with [disease], but it’s, you know,
so linked and so connected, that I find there’s a direct,
you know, effect on the child through the parents, so
I’d like to see more supports, research for the parents
that are also kind of surviving through this…” –
Patient/caregiver 4
A common criticism is that many outcome measures,
including patient-oriented outcome measures, have not
been validated or standardized for the population of
interest, leading to questions about the applicability of
study results [4, 42, 70].
“… we know that some of these tests or some of the
questionnaires have not been standardized for these
particular populations, and we’re faced with always
the question is it clinically relevant for these patients?
I think overall, there’s agreement that they are, but we
run into this problem all the time with, you know,
Pompe or the different MPS’ because there hasn’t been
long enough natural history studies, there has not been
standardization of these tests, so we’re choosing these
measuring tools for these particular studies without
really knowing if they’re the best tools. And this is very
relevant for the quality of life questionnaires, we
sometimes use the SF36 or we use specific pain
criteria, APPT or something like that, but we haven’t
actually standardized this for these populations, so we
don’t actually know if what we’re measuring is
clinically relevant.” – Physician 5
In response to this criticism, some researchers have
begun to identify/develop and validate standard sets of
outcome measures that can be used in clinical research
evaluating treatment effectiveness in their populations
[4, 45, 76]. Another concern that has been raised with
respect to outcomes is that it may not be possible to use
the same outcome measure within the same disease if
there is substantial clinical heterogeneity among patients
[4, 42, 45, 84, 89]. Some authors and focus group partici-
pants also noted that clinical heterogeneity has implica-
tions for identifying the minimal clinically important
difference [42].
“…the main trial showed an improvement of 22.5
meters after 6 months in the six-minute walk test,
which there’s quite a variability in outcomes depending
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on which patients you’re looking at, but that the aver-
age improvement. What does that really mean is a
very difficult decision because for somebody that is
walking perhaps 300 meters in six minutes and
improves by 22.5 meters, that’s probably not clinically
significant, if we’re just looking at a six-minute walk
test. But, if someone is not very mobile at all and has
that improvement, we might actually have a more
clinically significant impact with that treatment.”
– Physician 5
Finally, some focus group participants expressed concern
about balancing subjective outcomes (e.g., patient-reported
quality of life) with more objective outcomes (e.g., bio-
markers of disease progression) because of possible placebo
effects with patient-reported outcomes.
“I think there needs to be a combination of objective
and subjective outcome measures and quality of life
measures because, certainly, quality of life is extremely
important, but my sense is that it’s a lot more
vulnerable to placebo effect. As well, just in the sense
that a lot of these families are extremely invested in
being on their therapy because it is their only
therapeutic option. And so by relying on quality of life
measures very heavily, I think we can end up
advocating for treatment for patients that aren’t really
clinically benefitting.” – Physician 6
Discussion
Randomized controlled trials have long been considered
the ‘gold standard’ in evidence-based medicine due to
their superior ability to maximize internal validity [5].
However, our review and focus group findings describe
criticisms of conventional explanatory RCTs to establish
treatment effectiveness for rare disease therapies. There
was agreement across the focus group interviews and
with the literature we reviewed that the main challenges
in generating robust treatment efficacy and effectiveness
evidence for rare diseases includes: i) limitations in
recruiting a sufficient sample size to achieve planned
statistical power for many rare diseases, especially those
with a low prevalence such as MPS; ii) difficulties in ac-
counting for characteristic clinical heterogeneity of many
rare diseases; and iii) frequent reliance on short-term,
surrogate outcomes whose clinical relevance is often un-
clear. We mapped these three perceived challenges and
associated methodological solutions to three interrelated
research paradigms that emerged from our data: i)
explanatory evidence generation, ii) comparative effect-
iveness/pragmatic evidence generation, and iii)
patient-oriented evidence generation. Discussions related
to explanatory evidence generation were the first to arise
in the rare disease literature (in 1992) and have persisted
through 2016, with 58% (35/60) of the reports we
reviewed examining this research paradigm. The para-
digm of comparative effectiveness/pragmatic evidence
generation, which was discussed in 50% (30/60) of
reports, emerged in the literature in the early 2000s and
has also persisted through 2016, with a substantial in-
crease in the number of reports in the literature over the
last decade. The paradigm of patient-oriented evidence
generation developed more recently in the literature
(beginning in 2010) and has been discussed in 25%
(15/60) of reports included in this review. Based on
the year of publication for the included studies, there
appears to be a shift in perspectives over time with
increased criticism of conventional explanatory RCTs
and associated recognition of the importance of prag-
matic and patient-oriented evidence generation in the
context of establishing treatment effectiveness for rare
diseases.
Several methodological solutions have been suggested
within each research paradigm to address the perceived
challenges that were identified both in the literature
and by our focus group participants. For explanatory
evidence generation, the potential solutions include:
study designs that incorporate elements to improve
statistical efficiency and reduce the required sample
size (e.g., factorial trials, adaptive designs, applying
Bayesian statistical methods), and study designs that
ensure receipt of or maximize time spent on active
treatment to help boost participation (e.g., randomized
placebo-phase designs, crossover/N-of-1 trials). For
comparative effectiveness/pragmatic evidence gener-
ation, study designs or features that have been pro-
posed to improve the external validity of study results
include: incorporating pragmatic elements into conven-
tional RCTs, registries/cohort studies, and hybrid
designs such as cmRCTs. For patient-oriented evidence
generation, authors and focus group participants
suggested that incorporating outcomes that are consid-
ered important by patients and their caregivers (e.g.,
health-related quality of life) is critical to improve the
applicability of study results.
Notably, though numerous non-conventional study
designs were described in the literature we reviewed, few
of the suggested approaches appear to have been applied
successfully in the context of rare diseases. Only 28%
(17/60) reports included in this review were considered
applications or case examples of a specific research
method. As suggested by Gupta and colleagues, the pau-
city of real-world application of these designs, particu-
larly the non-conventional explanatory RCT designs,
may be related to a lack of acceptance of unfamiliar
study designs [36]. New therapies for many rare diseases
are rapidly developing, so there is an increasing
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opportunity to apply some of these non-conventional
study design strategies to evaluate efficacy and effective-
ness of emerging treatments for rare diseases [Stockler-
Ipsiroglu et al. Innovations in therapies and evidence
creation for inborn errors of metabolism, in progress].
Among the suggested methodological strategies, there
are tradeoffs with respect to internal and external valid-
ity, some of which may be exacerbated in the context of
rare diseases. For example, external validity is compro-
mised in many explanatory RCTs in favour of maintain-
ing strong internal validity to reduce potential bias and
confounding. In addition, because of the small number
of individuals available to participate in research, relying
on randomization procedures to balance patient charac-
teristics (both known and unknown) will not always be
successful. By contrast, study designs that can better ac-
commodate clinical heterogeneity and enhance external
validity may introduce a risk of confounding and bias.
And while external validity can be compromised if the
outcomes(s) included in a study are not considered im-
portant by clinicians and patients, many patient-oriented
outcome measures require additional validation and
long-term follow-up. With these tradeoffs in mind,
strategies for both comparative effectiveness/pragmatic and
patient-oriented evidence generation are increasingly being
recognized as important for investigating the effectiveness
of treatments for rare diseases, with explanatory RCTs
becoming less dominant in the literature in recent years.
The results of our meta-narrative review corroborate
the conclusions of methodological reviews that have
focused on approaches to generating evidence for inter-
ventions for rare diseases [36, 39, 40, 42, 45, 46]. To our
knowledge, our study is the first to incorporate stake-
holder perspectives in addition to data from the published
literature and to include a description of how perspectives
have evolved over time using a meta-narrative review.
Many of the approaches described in previously published
reviews are specific to explanatory evidence generation.
For example, both Gupta and colleagues and Cornu and
colleagues provide algorithms that could be used by
researchers to facilitate decision-making about which ex-
planatory trial design to apply for a particular rare disease
research question [36, 40]. Previous reviews included lim-
ited discussion of pragmatic evidence generation, with the
exception of observational methods such as registries or
cohort studies [42, 46]. Gagne and colleagues were the
only authors among our reviewed studies to include an
in-depth discussion about strategies that could be used to
mitigate bias and confounding in observational studies of
interventions for rare diseases [46]. Previously published
reviews rarely mentioned patient-oriented outcomes in
the context of evidence generation related to rare diseases.
Our work is not without limitations. The search strat-
egy that was developed for the meta-narrative portion of
this study was not exhaustive, so there is a possibility
that some literature may have been missed. However,
our intention was to identify key literature on this topic.
In addition, we only had a single reviewer (KT) who
determined study eligibility, which could have led to se-
lection bias in the articles chosen; however, clear inclu-
sion and exclusion criteria were used and the study team
met several times to review selected literature and dis-
cuss emerging findings. We only conducted three focus
group interviews with a relatively small, convenience
sample of participants; consequently, we may have
missed some perspectives. Our patient/caregiver focus
group was particularly narrow in its focus on a single
group of rare diseases. Because we were able to leverage an
existing meeting of an otherwise geographically dispersed
group of patients and families with MPS, an advantage of
our approach was the ability to conduct an in-person focus
group interview and thus ascertain the views of the partici-
pants more fully. However, some of the perspectives may
have been specific to that disease group and future research
could explore the perspectives of patients and families with
other rare diseases, including those with a relatively higher
prevalence for whom conventional explanatory studies
might be more feasible (e.g., cystic fibrosis).
Conclusions and future directions
Through our meta-narrative literature review and focus
group interviews we identified several perceived chal-
lenges and potential solutions for generating robust
treatment effectiveness evidence for rare diseases
according to three interrelated research paradigms: ex-
planatory, comparative effectiveness/pragmatic, and
patient-oriented evidence generation. Over time, there
has been more recognition that observational studies,
such as patient registries and cohort studies, are import-
ant approaches for clinical evaluative research in the
context of rare diseases to address gaps in comparative
effectiveness/pragmatic and patient-oriented evidence
generation. Developing better methods to mitigate po-
tential bias and confounding would increase the value of
these approaches for establishing treatment effectiveness
in the rare disease context. From a policy perspective,
there is a need for inclusive discussions amongst patients
and their families, clinicians, and policy advisors, includ-
ing those involved in regulatory and reimbursement
decision-making about interventions for rare diseases, in
order to identify solutions that meet the needs of all
stakeholder groups. Finally, little research has been done
with respect to developing knowledge synthesis methods
that consider the challenges faced in generating robust
evidence for rare diseases. Future directions for our
work include developing a framework to expand current
evidence synthesis practices to take into consideration
many of the concepts discussed in this paper.
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